Ad hoc Announcement according to Art. 17 Market Abuse Regulation
Aug 21 2020

Ad hoc Announcement according to Art. 17 Market Abuse Regulation

Resignation of Chairman of the Supervisory Board

Venlo, The Netherlands, August 21, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that Dr. Håkan Björklund, Chairman of the Supervisory Board, has resigned from office as Chairman of the Supervisory with immediate effect and has left the Supervisory Board. Dr. Björklund was appointed as member of the Supervisory Board of QIAGEN in March 2017 and served as Chairman since June 2018.

Lawrence A. Rosen has been elected by the Supervisory Board as new Chairman of the Supervisory Board. Mr. Rosen has been a member of the Supervisory Board since 2013.

 

QIAGEN N.V.

Hulsterweg 82

5912 PL Venlo

The Netherlands

 

ISIN: NL0012169213

Frankfurt Stock Exchange, Regulated Market (Prime Standard)

 

Contacts QIAGEN N.V.:

Corporate Communications

John Gilardi, Tel: 49 2103 29 11711; john.gilardi@qiagen.com

 

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2020, QIAGEN employed more than 5,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

FOLLOW US ON SOCIAL MEDIA

Share this page